Skip to main content




In June 2017, Actelion became part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Headquartered in Allschwil, a town on the western suburb of Basel, Switzerland. Actelion is an industry leader in the field of pulmonary hypertension (PH), and most notably, pulmonary arterial hypertension (PAH). Click here to see the acquisition press release.

As Actelion is being integrated into Janssen, you can click on each country to see their 2018 Transfer of Value data.

To learn more about PH, Actelion and its medicines, please visit or follow @actelion_com.